drugset / Trial / NCT07182591
A Study of DS5361b in Participants With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study aims to assess the safety, tolerability, and preliminary efficacy and to determine the MTD of DS5361b in monotherapy and combination with pembrolizumab in participants with advanced or metastatic solid tumors.
Timeline
- Start
- 2025-10-02
- Primary completion
- 2030-03-18
- Completion
- 2030-12-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DS5361b | Unknown | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |